Notice Regarding Difference Between Financial Forecast and Actual Results and Revision
Filed with TSE · · 2 pages · English
Summary by 6ix AI
The actual results showed a decline in net sales compared to the forecast, while operating and ordinary profits exceeded expectations due to lower expenses. The company also revised its full-year forecasts, reflecting the impact of an upfront payment related to a licensing agreement and losses from the transfer of its generic drug business.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
On 6ix: 6ix.com/news/notice-regarding-difference-between-financial-forecast-and-actual-results-and-revision
KYORIN Pharmaceutical Co.,Ltd. on 6ix
In the deck
Story so far
Earlier from KYORIN Pharmaceutical Co.,Ltd
- Notice Concerning Change in Major Shareholder
- (Update on Disclosed Matter) Notice Regarding Transfer of Generic Drug Business
- KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
- [Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]
- KYORIN Entered into Joint Marketing Agreement in Japan for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%
Follow KYORIN Pharmaceutical Co.,Ltd into a list and get an email when it puts out news.
Follow KYORIN Pharmaceutical Co.,Ltd